
    
      Data collection will be limited to study subjects 18 years or older who have received a
      hereditary cancer genomic diagnostic test results no more than 90 days prior to consent. The
      genes evaluated may be modified from time to time by the Sponsor as the body of knowledge
      expands and important additional pathways are identified. The list of appropriate genes that
      may be considered by the treating physician includes but are not necessarily limited to the
      following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2,
      MSH6, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, TP53 and XRCC2. These subjects
      must also meet medical necessity for hereditary cancer genomic testing; and allow physician
      to test based on medical necessity. Hereditary Cancer testing will be diagnostic rather than
      screening in nature.

      Study subject data will be collected only if medical necessity was established, subject
      agreed to test based on medical necessity and hereditary cancer genomic test was ordered by a
      physician related to individual study subject care considerations. The hereditary Cancer
      testing is independent of this data-collection, non- interventional study. The hereditary
      cancer genomic test must be ordered according to the individual study subject care
      considerations, it is not protocol specified, and will not be considered as "research" that
      is part of the study. Rather, the use of hereditary cancer genomic testing serves as criteria
      for eligibility in the study and must have been ordered for medical necessity and results
      received no less than 90 days prior before data is collected.

      The primary goal of the study is to record data over the observation period to evaluate the
      clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary
      genetic cancer risk profile and to help guide physicians to pursue preventative measures,
      which may lead to early detection and treatment of the condition; and to record physician
      recommended treatments and subject's brief medical history, demographic data; and
      investigator specialty.

      Such genetic test results and recommended treatments can be tabulated and analyzed to
      demonstrate the clinical utility of using hereditary cancer genomic diagnostics for
      prevention, early detection and treatment of the condition.

      The data will be collected retrospectively for a total of 120 no more than 150 days over the
      observation period in one (1) Case Report Form (survey). Similarly, the secondary objectives
      will be tabulated over the same observation period.

      An interim analysis of data will be performed to determine if the study subject data
      collection should be increased or decreased in order to fulfill study objectives.
    
  